Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 5
2004 1
2005 1
2006 4
2008 4
2009 5
2010 1
2011 3
2012 4
2013 3
2014 6
2015 7
2016 5
2017 9
2018 8
2019 10
2020 7
2021 18
2022 16
2023 7
2024 17
2025 18
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B.
Hou J, Zhang W, Xie Q, Hua R, Tang H, Morano Amado LE, Yang SS, Peng CY, Su WW, Chuang WL, Kim DJ, Avihingsanon A, Kao JH, Leerapun A, Yuen MF, Asselah T, Liang X, Bo Q, Canducci F, Catanese MT, Chen E, Cheng C, Chughlay F, Das S, Glavini K, Guerreiro N, Huang Y, Kakrana P, Kazma R, Patil A, Pavlovic V, Surujbally B, Triyatni M, Upmanyu R, Wat C, Gane E; Piranga Study Group. Hou J, et al. Among authors: yang ss. N Engl J Med. 2024 Dec 5;391(22):2098-2109. doi: 10.1056/NEJMoa2405485. N Engl J Med. 2024. PMID: 39774313 Clinical Trial.
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Djedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z; STELLAR-3; STELLAR-4 Investigators. Harrison SA, et al. J Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6. J Hepatol. 2020. PMID: 32147362 Clinical Trial.
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial.
Lim YS, Yu ML, Choi J, Chen CY, Choi WM, Kang W, Kim GA, Kim HJ, Lee YB, Lee JH, Park NH, Kwon SY, Park SY, Kim JH, Choi GH, Jang ES, Chen CH, Hsu YC, Bair MJ, Cheng PN, Tung HD, Chang TS, Lo CC, Tseng KC, Yang SS, Peng CY, Han S. Lim YS, et al. Among authors: yang ss. Lancet Gastroenterol Hepatol. 2025 Apr;10(4):295-305. doi: 10.1016/S2468-1253(24)00431-X. Epub 2025 Feb 3. Lancet Gastroenterol Hepatol. 2025. PMID: 39914435 Clinical Trial.
Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
Antonuzzo L, Takahashi H, Park JO, Sookprasert A, Gillmore R, Yang SS, Cundom J, Petrova M, Vaccaro G, Holmblad M, Żotkiewicz M, Wang J, Rokutanda N, Oh DY. Antonuzzo L, et al. Among authors: yang ss. Oncologist. 2025 Jul 4;30(7):oyaf148. doi: 10.1093/oncolo/oyaf148. Oncologist. 2025. PMID: 40622010 Free PMC article. Clinical Trial.
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study.
Lee SW, Yang SS, Tsai PC, Huang CF, Chen CY, Hung CH, Chen CH, Tai CM, Cheng PN, Kuo HT, Tseng KC, Mo LR, Lo CC, Huang YH, Lin HC, Lee PL, Bair MJ, Chang TS, Lin CY, Wang SJ, Hsieh TY, Yang TH, Peng CY, Yang CC, Chong LW, Huang CW, Lin CW, Chu CH, Tsai MC, Kao JH, Liu CJ, Chuang WL, Lee TY, Yu ML; TACR investigators. Lee SW, et al. Among authors: yang ss. Clin Mol Hepatol. 2025 Jul;31(3):899-913. doi: 10.3350/cmh.2024.1015. Epub 2025 Feb 5. Clin Mol Hepatol. 2025. PMID: 39905837 Free PMC article.
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan.
Wang SJ, Chang TS, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Bair MJ, Yeh ML, Peng CY, Cheng CY, Huang JF, Lin CL, Yang CC, Kuo HT, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Wang SC, Dai CY, Kao JH, Lin HC, Chuang WL, Tseng KC, Chen CY, Huang CF, Yu ML. Wang SJ, et al. Among authors: yang ss. Kaohsiung J Med Sci. 2025 Nov;41(11):e70067. doi: 10.1002/kjm2.70067. Epub 2025 Jun 20. Kaohsiung J Med Sci. 2025. PMID: 40539474 Free PMC article.
139 results